Literature DB >> 28585328

The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment.

A Tripodi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28585328     DOI: 10.1111/jth.13750

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  1 in total

1.  Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

Authors:  Nicolas Gendron; Juliette Gay; Marine Lemoine; Pascale Gaussem; Agnès Lillo-Le-Louet; David M Smadja
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.